Fate Therapeutics (FATE) analyst forecast and price target
Analyst forecast
Consensus of 11 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $7.00 | Aug 14, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $3.50 from $2.50 | Aug 14, 2026 |
| Piper Sandler | Maintained | Overweight | $8.00 from $6.00 | Aug 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Jun 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 from $5.00 | May 4, 2026 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $5.00 | Oct 31, 2025 |
| Needham | Maintained | Hold | — | Oct 27, 2025 |
| Wedbush | Upgraded | Neutral → Outperform | $7.00 from $5.00 | Oct 27, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $2.50 from $4.00 | Aug 13, 2025 |
| Needham | Maintained | Hold | — | Jun 12, 2025 |
| Needham | Maintained | Hold | — | May 14, 2025 |
| Baird | Maintained | Neutral | $4.00 from $5.00 | May 14, 2025 |
| Barclays | Maintained | Overweight | $2.00 from $10.00 | May 14, 2025 |
| Needham | Maintained | Hold | — | Mar 6, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $4.00 from $5.00 | Mar 6, 2025 |
| Wedbush | Maintained | Neutral | $5.00 | Mar 6, 2025 |
| Stifel | Maintained | Hold | $3.00 from $5.00 | Mar 6, 2025 |
| Needham | Maintained | Hold | — | Nov 19, 2024 |
| Needham | Maintained | Hold | — | Nov 13, 2024 |
| HC Wainwright & Co. | Maintained | Neutral | $5.00 | Aug 22, 2024 |
Frequently asked questions
What is the price target for FATE stock?
The average 12-month analyst price target for Fate Therapeutics (FATE) is $6.17, with a high estimate of $8.00 and a low of $3.50, across 3 analysts.
Is FATE a buy, sell, or hold?
Analysts covering Fate Therapeutics currently average a Buy rating: 6 buy, 5 hold and 0 sell, from 11 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for FATE?
The average price target of $6.17 implies 195.76% upside from the last price of $2.09.
What is the latest analyst rating on FATE?
On Aug 14, 2026, Wedbush maintained Fate Therapeutics at Outperform with a price target of $7.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.